靶向血管生成素/酪氨酸蛋白激酶-2(Ang/Tie2)通路的脓毒症治疗药物的研究进展  

Advances in drug for sepsis targeting Angs/Tie2 pathway

作　　者：姜萌 薛立超 郝淑兰[1] 仲启明[1] 冯玛莉[1] 王晞星[1] 吉海杰[1] JIANG Meng;XUE Lichao;HAO Shulan;ZHONG Qiming;FENG Mali;WANG Xixing;JI Haijie(Shanxi Traditional Chinese Medical Hospital,Shanxi Province Academy of Traditional Chinese Medicine,Taiyuan 030012,China;Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences.Taiyuan 030032,China)

机构地区：[1]山西省中医院山西省中医药研究院,山西太原030012 [2]山西白求恩医院山西医学科学院,山西太原030032

出　　处：《现代药物与临床》2024年第4期1053-1060,共8页Drugs & Clinic

基　　金：国家自然科学基金面上项目(81973672);山西省“四个一批”科技兴医创新计划(2020SYS06);山西省基础研究计划(202203021221291);山西省科技创新人才团队(202204051001032)。

摘　　要：脓毒症是一种由细菌等病原微生物侵入机体引起的全身炎症反应综合征,常伴有器官功能障碍、组织灌注不良、低血压甚至脓毒性休克。血管功能障碍与脓毒症之间存在明确的关系。血管生成素/酪氨酸蛋白激酶-2(Ang/Tie2)通路可以作为控制炎症、防止血管渗漏药物研发的重要靶点,为脓毒症治疗提供新的可能性。靶向Ang/Tie2通路的脓毒症治疗药物有重组人Ang1腺病毒、Ang1类似物、Ang2抑制剂、重组人Ang2和Tie2激动剂。总结了靶向Ang/Tie2通路的脓毒症治疗药物的研究进展,以期为脓毒症治疗药物的开发提供思路。Sepsis is a systemic inflammatory response syndrome caused by the invasion of pathogenic microorganisms such as bacteria into the body,often accompanied by organ dysfunction,poor tissue perfusion,hypotension,and even septic shock.There is a clear relationship between vascular dysfunction and sepsis.The angiopoietin/tyrosine protein kinase-2(Ang/Tie2)pathway can serve as an important target for the development of drugs to control inflammation and prevent vascular leakage,providing new possibilities for the treatment of sepsis.The therapeutic drugs targeting the Ang/Tie2 pathway for sepsis include recombinant human Ang1 adenovirus,Ang1 analogues,Ang2 inhibitors,recombinant human Ang2,and Tie2 agonists.This article summarizes the research progress of drugs for sepsis targeting the Ang/Tie2 pathway,aiming to provide ideas for the development of sepsis treatment drugs.

关 键 词：重组人Ang1腺病毒 Ang1类似物 Ang2抑制剂 重组人Ang2 Tie2激动剂 血管生成素/酪氨酸蛋白激酶-2通路 脓毒症 内皮功能障碍 

分 类 号：R976[医药卫生—药品]